Construction of a nomogram model to predict the risk of retinopathy of prematurity reactivate after intravitreal anti-vascular endothelial growth factor therapy: a retrospective study

被引:0
|
作者
Shen, Ziyun [1 ]
Hao, Qingfei [1 ]
Yang, Tiantian [1 ]
Cheng, Xiuyong [1 ]
机构
[1] Zheng Zhou Univ, Affiliated Hosp 1, Dept Neonatol, Zhengzhou, Peoples R China
来源
FRONTIERS IN PEDIATRICS | 2025年 / 12卷
关键词
anti-vascular endothelial growth factor; retinopathy of prematurity; reactivate; nomogram; preterm; BLOOD-TRANSFUSION; BEVACIZUMAB; MANAGEMENT; INFANTS;
D O I
10.3389/fped.2024.1440437
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective To explore the risk factors for the reactivate of retinopathy of prematurity (ROP) after intravitreal injection of anti-vascular endothelial growth factor (VEGF) and to construct a nomogram model to predict the risk of ROP reactivate. Methods A retrospective analysis was conducted on 185 ROP children who underwent anti-VEGF treatment at the First Affiliated Hospital of Zhengzhou University from January 2017 to October 2023. They were randomly divided into a training set (129 cases) and a validation set (56 cases) at a ratio of 7:3. The training set was further divided into a reactivate group (n = 18) and a non-reactivate group (n = 111) based on whether ROP recurred after treatment. Multivariable logistic regression analysis was used to screen for risk factors for ROP reactivate. A nomogram model was constructed using R software and validated using the validation set. The discrimination, calibration, and clinical net benefit of the model were evaluated using the receiver operating characteristic curve (ROC curve), calibration curve, and decision curve analysis, respectively. Results Multivariable logistic regression analysis showed that the number of red blood cell transfusions, use of pulmonary surfactant (PS) 2 times or more, and preoperative fundus hemorrhage were independent risk factors for ROP reactivate (P < 0.05). The area under the ROC curve (AUC) of the training set was 0.810 (95% CI: 0.706-0.914), and that of the validation set was 0.756 (95% CI: 0.639-0.873). The Hosmer-Leme show goodness-of-fit test indicated a good fit of the model (P = 0.31). Calibration curve analysis and decision curve analysis suggested high predictive efficacy and clinical application value of the model. Conclusions The number of red blood cell transfusions, use of PS 2 times or more, and preoperative fundus hemorrhage are independent risk factors for ROP reactivate. The nomogram model constructed based on these factors has high predictive efficacy and clinical application value.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Beyond Intravitreal Injection of Anti-Vascular Endothelial Growth Factor (VEGF) Therapy
    d'Amico, G.
    Caporossi, T.
    Pagliara, M. M.
    Molle, F.
    Lepore, D.
    Focosi, F.
    Balestrazzi, E.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)
  • [42] Subconjunctival hemorrhage after intravitreal injection of anti-vascular endothelial growth factor
    Cheolmin Yun
    Jaeryung Oh
    Soon-Young Hwang
    Seong-Woo Kim
    Kuhl Huh
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2015, 253 : 1465 - 1470
  • [43] Subconjunctival hemorrhage after intravitreal injection of anti-vascular endothelial growth factor
    Yun, Cheolmin
    Oh, Jaeryung
    Hwang, Soon-Young
    Kim, Seong-Woo
    Huh, Kuhl
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2015, 253 (09) : 1465 - 1470
  • [44] The role of anti-vascular endothelial growth factor in treatment of retinopathy of prematurity-a current review
    Chow, Shing Chuen
    Lam, Pun Yuet
    Lam, Wai Ching
    Fung, Nicholas Siu Kay
    EYE, 2022, 36 (08) : 1532 - 1545
  • [45] Short-term effects of intravitreal anti-vascular endothelial growth factor agents on body weight and multiple systems after treatment for retinopathy of prematurity
    Chen, Jing
    Hao, Qingfei
    Zhang, Jing
    Du, Yanna
    Chen, Haoming
    Cheng, Xiuyong
    FRONTIERS IN PEDIATRICS, 2023, 10
  • [46] Intravitreal Anti-Vascular Endothelial Growth Factor Agents for the Treatment of Diabetic Retinopathy: A Review of the Literature
    Chatziralli, Irini
    Loewenstein, Anat
    PHARMACEUTICS, 2021, 13 (08)
  • [47] REPORT OF SAFETY OF THE USE OF A SHORT 32G NEEDLE FOR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS FOR RETINOPATHY OF PREMATURITY
    Cernichiaro-Espinosa, Linda A.
    Harper, Clio A., III
    Read, Sarah P.
    Wright, Lauren M.
    Scribbick, Frank W., III
    Young, Ryan
    Negron, Catherin I.
    Rodriguez, Ana
    Berrocal, Audina M.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2018, 38 (06): : 1251 - 1255
  • [48] Pulmonary Hypertension in Preterm Infants Treated With Laser vs Anti-Vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity
    Nitkin, Christopher R.
    Bamat, Nicolas A.
    Lagatta, Joanne
    DeMauro, Sara B.
    Lee, Henry C.
    Patel, Ravi Mangal
    King, Brian
    Slaughter, Jonathan L.
    Campbell, J. Peter
    Richardson, Troy
    Lewis, Tamorah
    JAMA OPHTHALMOLOGY, 2022, 140 (11) : 1085 - 1094
  • [49] PLASMA CONCENTRATIONS OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN RETINOPATHY OF PREMATURITY AFTER INTRAVITREAL BEVACIZUMAB INJECTION
    Hong, Yoo Rha
    Kim, Young Ho
    Kim, Soo Young
    Nam, Gi Yup
    Cheon, Hee Jong
    Lee, Sang Joon
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2015, 35 (09): : 1772 - 1777
  • [50] A comparison of primary laser versus laser after anti-vascular endothelial growth factor for type 1 retinopathy of prematurity
    Lajoie, Juliann E.
    Pacheco, Richard R.
    Shah, Virali
    Tauber, Kate A.
    Binenbaum, Gil
    Barry, Gerard P.
    JOURNAL OF AAPOS, 2022, 26 (04): : 191.e1 - 191.e4